



# InflammaDry®

## Dry Eye

### Have confidence in your diagnosis

The lack of correlation between clinical signs and symptoms of dry eye disease makes diagnosing and treating patients a challenge. Often times, inflammation is present before the clinical signs of dry eye.<sup>1</sup>

InflammaDry is the first rapid, in-office CLIA-waived test that detects elevated levels of MMP-9, an inflammatory marker that is consistently elevated in the tears of patients with dry-eye disease. Other dry-eye tests only measure tear production and stability. InflammaDry accurately identifies patients with dry eye allowing for optimal treatment methods and better quality of life.

#### Clinical benefits

- Pre-surgical measurements are more accurate and post-surgical outcomes are improved by identifying and treating patients with dry eye.<sup>2</sup>
- Reduce post-surgical complications, such as corneal wound healing, by identifying dry eye prior to surgery.<sup>1</sup>
- Therapeutic treatment of dry eye improves patient quality of life.<sup>4</sup>

#### Fast and accurate

- Results as soon as 10 minutes.
- Higher positive and negative agreement than other dry-eye tests.


#### Easy and convenient

- Disposable test, requires just 4 easy steps.
- No additional equipment is needed to administer or interpret.



## 4-Step Procedure

Collect sample




Assemble test




Run test



Read results



## Performance Characteristics



Positive % Agreement



Negative % Agreement

The multicenter clinical study demonstrated the following range of performance from site to site or between sites ranging from: Positive % Agreement 66% to 97% and Negative % Agreement 97% to 98%. At two sites, Negative Agreement could not be calculated because there were no subjects without dry eye.

Refer to the Package Insert for additional performance claims.

To order, contact your Quidel Account Manager, call Customer Service at 800.874.1517, or visit [quidel.com/InflammaDry](http://quidel.com/InflammaDry)

<sup>1</sup>Sambursky R., O'Brien T.P. MMP-9 and the perioperative management of LASIK surgery. *Curr Opin Ophthalmol*. 2011 Jul 22; 22(4): 294-303.

<sup>2</sup>Shtein R.M. Post-LASIK dry eye. *Expert Rev Ophthalmol*. 2011 Oct; 6(5): 575-582.

<sup>3</sup>Schiffman R.M., Walt J.G., Jacobsen G. et al. Utility assessment among patients with dry eye disease. *Ophthalmol*. 2003 Jul; 110(7): 1412-9.